(NASDAQ: KROS) Keros Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.35%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.91%.
Keros Therapeutics's earnings in 2026 is -$85,145,000.On average, 10 Wall Street analysts forecast KROS's earnings for 2026 to be -$117,579,345, with the lowest KROS earnings forecast at -$156,913,642, and the highest KROS earnings forecast at -$100,374,301. On average, 10 Wall Street analysts forecast KROS's earnings for 2027 to be -$109,185,627, with the lowest KROS earnings forecast at -$166,805,602, and the highest KROS earnings forecast at -$50,914,501.
In 2028, KROS is forecast to generate -$91,113,701 in earnings, with the lowest earnings forecast at -$173,206,282 and the highest earnings forecast at -$45,511,329.